Fate Therapeutics

Home    Contact Us
Skip to content
  • About Us
    • Management
    • Board of Directors
    • Founders
    • Investors
    • Corporate Fact Sheet
  • Therapeutic Programs
    • ProHema
    • eHSCs
    • FT301
    • FT201
    • FT101
    • Hearing Restoration
  • Research
    • Cell state characterization
    • iPSC
  • Partnerships
    • Becton Dickinson
    • United States Army
  • Human Resources
    • Open Positions
  • Learn More
    • Press Releases
    • Publications
    • Awards
Home
Home
Uniting our unmatched knowledge of stem cell biology with a relentless pursuit of new discoveries to develop therapeutics that modulate pathways of cell fate
Press Releases
Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO
December 14, 2011
 
Fate Therapeutics announces promising data from Phase 1B study of ProHema at the 2011 American Society of Hematology Annual Conference
December 13, 2011
 
Fate Therapeutics secures foundational patent for IPS cell programming
December 8, 2011
 
© 2012 Fate Therapeutics
|
Legal
|
Glossary